Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
05/2003
05/14/2003EP1309573A1 Urethane derivatives
05/14/2003EP1309571A1 Non-steroidal inflammation inhibitors
05/14/2003EP1309560A1 Pyridine derivatives as inhibitors of p38
05/14/2003EP1309552A1 Compounds and inhibitors of phospholipases
05/14/2003EP1309549A1 Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia
05/14/2003EP1309544A1 Compounds acting as melanocortin receptor ligands
05/14/2003EP1309355A1 Peptide and peptide mimetic conjugates with integrin-inhibitor properties
05/14/2003EP1309354A2 Therapeutic polyesters and polyamides
05/14/2003EP1309334A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
05/14/2003EP1309331A2 Medicine for fighting against sexual dysfunction
05/14/2003EP1192170B1 Propargyl phenyl ether a2a receptor agonists
05/14/2003EP1192169B1 C-pyrazole a2a receptor agonists
05/14/2003EP1180105B1 Substituted aza-oxindole derivatives
05/14/2003EP1140905B1 Heteroaromatic amides as inhibitor of factor xa
05/14/2003EP1112266B1 Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same
05/14/2003EP1102746B1 Substituted phenylamidines with antithrombotic action
05/14/2003EP1036095A4 Oxygen-transporting albumin-based blood replacement composition and blood volume expander
05/14/2003CN1418187A Carboxylic acid derivatives as IP antagonists
05/14/2003CN1418096A IL-8 receptor antagonists
05/14/2003CN1418091A Pharmaceutical preparations
05/14/2003CN1416856A Medicine for treating aplastic anemia
05/13/2003WO2002040048A2 Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis
05/13/2003US6562995 Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters are disclosed. The novel compounds have two carbonyl groups connected by a linking moiety having
05/13/2003US6562988 16-HETE (16-hydroxyeicosatetraenoic acid) analogues such as the methanesulfonamide ester (-CO-NH-SO2-CH3); inhibiting neutrophil adhesion and neutrophil aggregation; treating stroke, inflammatory diseases
05/13/2003US6562872 Emulsion of perfluoroorganic compounds for medical purposes, a process for the preparation thereof and methods for treating and preventing diseases with the use thereof
05/13/2003US6562843 For treating disorders ameliorated by a reduction in TNF-alpha production and/or p38 activity, and are therefore useful for treating inflammatory disorders such as rheumatoid arthritis, as well as AIDS-related disorders
05/13/2003US6562837 Use of tetrahydroisoquinoline compounds for the treatment of septicemia
05/13/2003US6562828 Amidine compounds
05/13/2003US6562825 For treating inflammatory disease including asthma and allergic diseases, as well as autoimmune pathologies
05/13/2003US6562781 Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
05/13/2003US6562598 Factor X deletion mutants and analogues thereof
05/13/2003CA2428649A1 Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis
05/13/2003CA2127876C Imidazole derivatives and their use as cytokine inhibitors
05/08/2003WO2003038110A2 7118, a human arginine n-methyltransferase family member and uses therefor
05/08/2003WO2003038071A1 Detection of haematopoietic stem cells and progeny and uses thereof
05/08/2003WO2003038043A2 Combinations of dr5 antibody and other therapeutic agents
05/08/2003WO2003037932A2 Human coagulation factor vii polypeptides
05/08/2003WO2003037913A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
05/08/2003WO2003037901A1 Bridged bicycle (1,4) benzodiazepine vasopressin receptor antagonists
05/08/2003WO2003037899A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003WO2003037877A1 AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS
05/08/2003WO2003037874A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003WO2003037869A1 Amide derivatives as glycogen synthase kinase 3-beta inhibitors
05/08/2003WO2003037852A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
05/08/2003WO2003037847A1 Benzamide derivatives as antagonists of orexin receptors
05/08/2003WO2003037433A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
05/08/2003WO2003037432A1 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
05/08/2003WO2003037363A2 Non-neurotoxic plasminogen activating factors for treating stroke
05/08/2003WO2003037362A2 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
05/08/2003WO2003037352A1 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
05/08/2003WO2003037351A1 Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
05/08/2003WO2003037336A1 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
05/08/2003WO2003037335A1 5-heteroatom-substituted pyrazoles
05/08/2003WO2003037330A1 Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
05/08/2003WO2003037268A2 Hepta-, octa- and nonapeptides having antiangiogenic activity
05/08/2003WO2003037220A1 Improved endoprosthetic device
05/08/2003WO2003037168A2 Methods and formulations for minimizing spasticity in blood vessel grafts
05/08/2003WO2003037164A2 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
05/08/2003WO2003023404A8 A method of diagnosis and treatment and agents useful for same
05/08/2003WO2003022192B1 Eustachian tube stent
05/08/2003WO2002081499A3 Somatostatin agonists
05/08/2003WO2002072608A3 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
05/08/2003WO2002060897A3 Process for making substituted 8-arylquinolinium benzenesulfonate
05/08/2003WO2002057226A3 68730 and 69112 protein kinase molecules and uses therefor
05/08/2003WO2002026946A3 Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof
05/08/2003WO2002010216A3 Proteins and nucleic acids encoding same
05/08/2003US20030088111 Protected forms of pharmacologically active agents and uses therefor
05/08/2003US20030088085 MPROT12 polynucleotides and methods thereof
05/08/2003US20030087922 Aryl substituted 2-aminopyrimidines and 2-aminopyridines
05/08/2003US20030087921 Especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa.
05/08/2003US20030087919 Rho-kinase inhibitors
05/08/2003US20030087909 Having an attached non-aromatic heterocyclic ring
05/08/2003US20030087892 Condensed azepines as vasopressin agonists
05/08/2003US20030087878 Methods and formulations for minimizing spasticity in blood vessel grafts
05/08/2003US20030087826 Conjugates comprising two active agents
05/08/2003US20030087817 Regulation of endogenous gene expression in cells using zinc finger proteins
05/08/2003US20030087816 Anticancer, antitumor agents; genetic engineering
05/08/2003US20030087801 Methods for treatment using novel ligands of the neuropeptide receptor hfgan72
05/08/2003US20030087384 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment fibroblast growth factor receptor defects
05/08/2003US20030087264 Detection of regulatory response to pulsatile electromagnetic stimulus; obtain tissue sample, insert probe, apply pulsatile stimulus, detect gene expression, classify genes which are expresed
05/08/2003US20030087249 93870, a human G-protein coupled receptor and uses therefor
05/08/2003US20030086914 Method and device for inducing biological processes by micro-organs
05/08/2003CA2466824A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003CA2465792A1 Non-neurotoxic plasminogen activating factors for treating of stroke
05/08/2003CA2465632A1 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
05/08/2003CA2465497A1 Bridged bicyclic amino acid-derived (1,4) benzodiazepine vasopressin receptor antagonists
05/08/2003CA2465314A1 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
05/08/2003CA2465040A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
05/08/2003CA2464956A1 Detection of haematopoietic stem cells and progeny and uses thereof
05/08/2003CA2464944A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003CA2464727A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
05/08/2003CA2464479A1 Methods and formulations for minimizing spasticity in blood vessel grafts
05/08/2003CA2463823A1 Aminobenzamide derivatives as glycogen synthase kinase 3.beta. inhibitors
05/08/2003CA2463821A1 Amide derivatives as glycogen synthase kinase 3-beta inhibitors
05/08/2003CA2426785A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
05/07/2003EP1308511A1 Use of angiopoietin-like 1 and angiopoietin-like 2 nucleic acids and proteins for the treatment of blood-related disorders and defects in vasculature.
05/07/2003EP1308446A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/07/2003EP1308445A1 5-heteroatom-substituted pyrazoles
05/07/2003EP1308441A1 2-aminopyridine compounds and use thereof as drugs
05/07/2003EP1308179A1 Improved endoprosthetic device
1 ... 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 ... 671